1,719 results on '"Ratziu, Vlad"'
Search Results
352. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study
353. Pharmacological therapy for non-alcoholic steatohepatitis: How efficient are thiazolidinediones?
354. Endpoints and clinical trial design for nonalcoholic steatohepatitis
355. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?
356. Insulin Sensitizers in Nonalcoholic Steatohepatitis
357. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19
358. Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers
359. Clinical endpoints are necessary in the interim analysis of REGENERATE – Authors' reply
360. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆
361. Metabolomics approaches to identify biomarkers of non-alcoholic fatty liver disease
362. Liver disease progression and clinical outcomes in hepatic outcomes and survival fatty liver registry (HOTSURFR) study
363. Macrophage scavenger receptor 1 mediates lipid-induced inflammation in human obesity-related non-alcoholic fatty liver disease
364. Obeticholic acid improves experimental non-invasive markers of non-alcoholic steatohepatitis and advanced fibrosis: a secondary analysis of the phase 3 regenerate study
365. Health-care burden of NAFLD in European hospital-based outpatient hepatology clinics: real-world prospective data from the CONSTANS study
366. Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric magnetic resonance imaging: interim results of the regenerate trial
367. Obeticholic acid demonstrates sustained improvements at month 24 in transaminases and non-invasive markers of fibrosis: results of a post hoc analysis from the interim analysis of the REGENERATE study
368. Metabolism of human liver on a genome scale in non-alcoholic fatty liver disease
369. Adipose tissue insulin resistance and inflammation, but not reduced hepatic fat oxidation, are associated to active NASH and severe fibrosis
370. Serum levels of miR-34a to rule-out NAFLD in healthy subjects and identify NAFLD patients with active NASH (NAS>= 4) and significant liver fibrosis (F >= 2)
371. Europe’s largest meta-analysis on the prevalence of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and advanced fibrosis (F3-F4)
372. NASH is emerging as a leading cause of hospitalisation for cirrhosis: results from a real-life, prospective, consecutive cohort
373. Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 vs. placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: a phase 2 randomised controlled trial (FASCINATE-1)
374. High-throughput sequencing identified MIR-193a as a potential biomarker of non-alcoholic fatty liver disease activity
375. Obesity-specific health-related quality of life in patients with non-alcoholic steatohepatitis: results from the regenerate study
376. Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum
377. EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a argon-1 study
378. Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis
379. A transcriptomic signature predicting fibrosis progression in a large European cohort of patients with histologically characterised NAFLD
380. Hepatic RIPK3 signalling differentially modulates lipid metabolism and inflammation in non-alcoholic fatty liver disease
381. The combination of elafibranor and semaglutide drastically improves fibrosing steatohepatitis and distinctly modulates liver inflammatory signature
382. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
383. Introducing the Expert Opinion series
384. Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice
385. Tu1665 OBETICHOLIC ACID IMPROVES HEPATIC FIBROINFLAMMATION AS ASSESSED BY MULTIPARAMETRIC MRI: INTERIM RESULTS OF THE REGENERATE TRIAL
386. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
387. Why do so many NASH trials fail?
388. Mo1448 OBETICHOLIC ACID IMPROVES TRANSAMINASES IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE 18-MONTH INTERIM ANALYSIS OF THE REGENERATE STUDY
389. 326 OBESITY-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE REGENERATE STUDY
390. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease
391. 334 OBETICHOLIC ACID IMPROVES EXPERIMENTAL NON-INVASIVE MARKERS OF NON-ALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS; RESULTS OF A SECONDARY ANALYSIS FROM THE MONTH-18 INTERIM ANALYSIS OF THE REGENERATE STUDY
392. Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed
393. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease
394. Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease
395. Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group
396. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
397. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
398. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
399. Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (Flirt 2) Extension Trial
400. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.